Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

Queen's University researcher Steven Lehrer has won a prestigious international award in recognition of his contributions to health economics. A professor in Queen's School of Policy Studies and Department of Economics, Dr. Lehrer shares the RAND Corporation's Victor R. Fuchs Research Award with Jason Fletcher of Yale University.

Queen's University researcher Steven Lehrer has won a prestigious international award in recognition of his contributions to health economics. A professor in Queen's School of Policy Studies and Department of Economics, Dr. Lehrer shares the RAND Corporation's Victor R. Fuchs Research Award with Jason Fletcher of Yale University.

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

What is INTUNIV for ADHD?

The active ingredient in INTUNIV is Guanfacine, normally thought of as the blood pressure medicine Tenex. INTUNIV is not a blood pressure medication, however. It is approved for the treatment of ADHD.

INTUNIV is not a stimulant, and its action on the brain is different than stimulants. INTUNIV is another ADHD medication from Shire Pharmaceuticals, where they seem to insist that all of their medications are spelled in all capital letters. Shire also makes and distributes ADDERALL XL, DAYTRANA, and VYVANSE. And since the sales of Adderall XR have been undercut by Teva's generic Adderall, and the sales of Vyvanse have been disappointing, Shire is hopeful that Intuniv will bolster its place in the ADHD marketplace. Read more of the article...

What is INTUNIV for ADHD?

The active ingredient in INTUNIV is Guanfacine, normally thought of as the blood pressure medicine Tenex. INTUNIV is not a blood pressure medication, however. It is approved for the treatment of ADHD.

INTUNIV is not a stimulant, and its action on the brain is different than stimulants. INTUNIV is another ADHD medication from Shire Pharmaceuticals, where they seem to insist that all of their medications are spelled in all capital letters. Shire also makes and distributes ADDERALL XL, DAYTRANA, and VYVANSE. And since the sales of Adderall XR have been undercut by Teva's generic Adderall, and the sales of Vyvanse have been disappointing, Shire is hopeful that Intuniv will bolster its place in the ADHD marketplace. Read more of the article...

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,has announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD.

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,has announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD.

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,has announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD.

Teachers and parents must be vigilant in observing difficulties with language comprehension, reading and spelling in children and young people with autism, Asperger's syndrome and ADHD. "It is important that pupils are offered the support to which they are entitled", says Jakob Asberg in a new thesis at the University of Gothenburg. "Pupils with these neuropsychiatric disorders are often reported as having problems with spoken and written activities.

Teachers and parents must be vigilant in observing difficulties with language comprehension, reading and spelling in children and young people with autism, Asperger's syndrome and ADHD. "It is important that pupils are offered the support to which they are entitled", says Jakob Asberg in a new thesis at the University of Gothenburg. "Pupils with these neuropsychiatric disorders are often reported as having problems with spoken and written activities.

BioBehavioral Diagnostics Company announced that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009. Calvin R. Sumner, M.D.

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). In addition, data regarding the pharmacokinetic profile of Daytrana in children and adolescents was also presented.

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV™ (guanfacine) Extended Release Tablets, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, and Daytrana® (methylphenidate transdermal system) CII, at a national meeting of psychiatrists being held October 27 - November 1 in Honolulu.

It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of The Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years. Researcher Dr.

Schoolchildren with attention deficit/hyperactivity disorder are substantially more likely to engage in many types of criminal activity such as burglary, theft and drug dealing as they grow older, a new study by the Yale School of Public Health has found. The research was published in The Journal of Mental Health Policy and Economics.

It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of The Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years. Researcher Dr.

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

Can Excessive Video Game Playing Cause Attention Problems?

Yes, its just like you thought. The more your child or teen sits around watching TV or playing video games, the more at risk they will be for learning problems and attention problems. We have written about this before, and not to much has changed except that the research is starting to show up to validate what parents have known for five years now. Read more of the article...